Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24221862 | 0.87 | MEN1 (0.49) | IDO1MEN1ALDH1A1KMT2AMAOA | |
| SCHEMBL21883255 | 0.81 | IDO1 (0.50) | IDO1MEN1ALDH1A1KMT2AMAOA | |
| SCHEMBL21883149 | 0.81 | KMT2A (0.52) | IDO1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL21883515 | 0.78 | NPC1 (0.51) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL32665823 | 0.78 | NPC1 (0.51) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL26991 | 0.78 | IDO1 (0.79) | IDO1MEN1ALDH1A1KMT2AMAOA | |
| SCHEMBL29481122 | 0.78 | IDO1 (0.79) | IDO1MEN1ALDH1A1KMT2AMAOA | |
| SCHEMBL21883121 | 0.75 | KMT2A (0.51) | IDO1MEN1ALDH1A1KMT2AMAOA | |
| SCHEMBL21883132 | 0.75 | NPC1 (0.51) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL21883248 | 0.75 | GAA (0.47) | IDO1MEN1ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024877-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | THE UAB RESEARCH FOUNDATION | 2022-01-27 | — | — | US | disclosed |
| WO-2020061412-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024877-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | SLC39A11, CNBP, SLC39A3 | IDO1 1055/4885MEN1 1706/4885ALDH1A1 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.